ABSTRACT
The COVID-19 pandemic prompted widespread primary and secondary school closures. Routine testing of asymptomatic students and staff, as part of a comprehensive program, can help schools open safely. “Pooling-in-a-pod” is a public health surveillance strategy whereby testing cohorts (pods) are based on social relationships and physical proximity. Pooled testing provides one laboratory result for the entire pod, rather than separate results for each individual. Pooling-in-a-pod allowed for weekly on-site point-of-care testing of all staff and students at an independent preschool to grade 12 school in Washington, D.C. Staff and older students self-collected anterior nares samples, and trained staff collected samples from younger students. Overall, 12,885 samples were tested in 1,737 pools for 863 students and 264 staff between November 30, 2020, and April 30, 2021. The average pool size was 7.4 people. Sample collection to pool result time averaged 40 minutes. Direct testing cost per person per week was $$24.24, including swabs. Four surveillance test pools were positive. During the study period, daily new cases in Washington, D.C., ranged from 10 to 46 per 100,000 population. A post-launch survey found most parents (90.3%), students (93.4%), and staff (98.8%) were willing to participate in pooled testing with confirmatory tests for positive pool members. The school reported a 73.4% decrease in virtual learning after program initiation. Pooling-in-a-pod is a feasible and cost-effective surveillance strategy that was acceptable to staff and families and may be appropriate for some schools. School officials and policymakers can leverage this strategy to facilitate safe, sustainable, in-person schooling.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
No external funding was used for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Office of Human Research Affairs at UnitedHealth Group
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version includes updated sample size as program continued and additional analysis.
Data Availability
De-identified data are available for review.
